AstraZeneca Announces US Availability of ZEGFROVY for NSCLC

AstraZeneca has announced the U.S. availability of ZEGFROVY (sunvozertinib) for patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutations who have progressed after platinum-based chemotherapy. The treatment is to be used in conjunction with an FDA-approved test for tumor identification, marking an expansion of AstraZeneca's oncology portfolio aimed at addressing challenging lung cancer mutations.